-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
(2020/08/11) New alzheimer's treatment - sEH inhibitors; Yangzijiang leader Enhua struggled to catch up; after the new drug was approved for listing requirements and research commitments: to achieve a thousand gold how much ... (Click on the title to obtain the original article) "Pharmaceutical 1st Time" Roche released new clinical data for etrolizumab UC Phase III clinical data Two maintenance treatments did not reach the end of the day, Roche Group member Genetek released its research drug etrolizumab on moderate to severe active ulcerative colitis (UC) patients in the series of phase 3 clinical studies of the top line data.
four studies, two etrolizumabs reached the primary endpoint of patient remission as an induced treatment, and two studies evaluating etrolizumab as maintenance therapy failed to reach the primary endpoint, with no significant difference in the proportion of patients who received remission mainly from intraskin injections.
: There's a huge market demand.
New treatment for Alzheimer's disease, the sEH inhibitor Alzheimer's disease, is a devastating neurodegenerative disease with unknown causes; it affects tens of millions of people worldwide in middle-aged and old age; it is the cause of 60-70% of dementia cases; the most common early symptom is the difficulty of remembering recent events, and as the disease progresses, the patient's physical function gradually loses, eventually leading to death; and the life expectancy after diagnosis is usually 39 years.
: Currently, Alzheimer's drugs have limited efficacy.
The number of Chinese enterprises in the top 500 exceeded that of the four U.S. pharmaceutical companies, surpassing BMS on August 10, Fortune magazine released the latest global 500 list, this year a total of 21 pharmaceutical companies on the list, four of which are the first to appear, respectively, Takeda Pharmaceuticals, Shanghai Pharmaceuticals, BMS and Seymru.
Fortune 500 is the most famous list of the world's largest companies and is known as the "ultimate list".
the list, which is based on revenue, this year's total revenue reached $33 trillion, a record high and close to the combined GDP of China and the United States.
headline: This Chinese mainland has made a historic leap forward.
The four giants of Jiangsu pharmaceutical companies are in the hundreds of billions of markets! Yangzijiang leader Enhua struggled to catch up, Enhua Pharmaceuticals released its first half 2020 results, net profit increased by nearly 10%.
Enhua Pharmaceuticals said that under the new bidding model of drug centralized belt procurement, the sales of products included in the collection in private hospitals have been increased, focusing on the marketing of non-collected products, improving the market share and sales scale of non-collected products, and achieving rapid growth in some products.
: China's public medical institutions in recent years, the growth rate of the terminal neurological drugs market slowed.
the new drug was approved for market requirements and research commitments: how much is a thousand dollars to do? As a condition of approval of new drugs or biological products, the FDA requires pharmaceutical companies to ensure that these drugs are approved for post-market clinical studies.
information on product safety, effectiveness, or best conditions of use.
of post-market clinical trials, which are scheduled to be conducted as required, how much is done? Recently, the FDA released an annual report on the performance of pharmaceutical companies in developing post-marketing requirements (post-marketing requirements, PMRs) and post-market commitments (post-market commitments, PMC) to report on implementation.
: What's the difference between PMR and PMC? The impact of the Panorama vaccine in China's vaccine industry on the protection of human health is enormous, making humans passive and active for the first time in the face of the threat of infectious diseases.
Through vaccination, small flowers have been eliminated, major infectious diseases such as polio, hepatitis B and measles have been effectively controlled, and the incidence of diseases such as cervical and head and neck cancer caused by HPV has been reduced.
: Vaccines are an important means of effective disease prevention.
.